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Background: Aldosterone synthase inhibition provides the potential to attenuate both the mineralocorticoid
receptor-dependent and independent actions of aldosterone. In vitro studies with recombinant human enzymes
showed LCI699 to be a potent, reversible, competitive inhibitor of aldosterone synthase (Ki = 1.4 ± 0.2 nmol/L in
humans) with relative selectivity over 11β-hydroxylase.
Methods: Hormonal effects of orally administered LCI699 were examined in rat and monkey in vivo models of
adrenocorticotropic hormone (ACTH) and angiotensin-II-stimulated aldosterone release, and were compared with
the mineralocorticoid receptor antagonist eplerenone in a randomized, placebo-controlled study conducted in
99 healthy human subjects. The effects of LCI699 and eplerenone on cardiac and renal sequelae of aldosterone
excess were investigated in a double-transgenic rat (dTG rat) model overexpressing human renin and angiotensinogen.
Results: Rat and monkey in vivo models of stimulated aldosterone release predicted human dose– and
exposure–response relationships, but overestimated the selectivity of LCI699 in humans. In the dTG rat model,
LCI699 dose-dependently blocked increases in aldosterone, prevented development of cardiac and renal functional
abnormalities independent of blood pressure changes, and prolonged survival. Eplerenone prolonged survival to a
similar extent, but was less effective in preventing cardiac and renal damage. In healthy human subjects, LCI699
0.5 mg selectively reduced plasma and 24 h urinary aldosterone by 49 ± 3% and 39 ± 6% respectively (Day 1, mean
± SEM; P < 0.001 vs placebo), which was associated with natriuresis and an increase in plasma renin activity. Doses
of LCI699 greater than 1 mg inhibited basal and ACTH-stimulated cortisol. Eplerenone 100 mg increased plasma
and 24 h urinary aldosterone while stimulating natriuresis and increasing renin activity. In contrast to eplerenone,
LCI699 increased the aldosterone precursor 11-deoxycorticosterone and urinary potassium excretion.
Conclusions: These results provide new insights into the cardiac and renal effects of inhibiting aldosterone
synthase in experimental models and translation of the hormonal effects to humans. Selective inhibition of
aldosterone synthase appears to be a promising approach to treat diseases associated with aldosterone excess.
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The pathogenesis of various forms of adrenal and low-
renin hypertension is attributed primarily to the renal
effects of excessive aldosterone on sodium retention and
potassium elimination [1]. Experimental data have shown
that aldosterone can cause cardiac, renal and vascular
damage independent of its effects on blood pressure [2].
These experimental data together with growing clinical
evidence for the benefits of blocking the actions of
aldosterone with mineralocorticoid receptor antagonists
(MRAs) in the treatment of heart failure [3-5] provide
the rationale for new therapeutic approaches to inhibit
aldosterone production. While MRAs are currently the
treatment of choice for pathologic conditions due to
aldosterone excess [6], they induce a counter-regulatory
increase in aldosterone production [7]. This may attenuate
the effects of competitive MRAs, and might also con-
tribute to adverse cardiovascular effects through non-
genomic mechanisms independent of activation of the
mineralocorticoid receptor [8-10]. An alternative approach
to inhibiting the effects of aldosterone is blocking the
renin-angiotensin system (RAS), which decreases aldoster-
one production indirectly. However, the resulting fall in
plasma aldosterone does not persist in the long term
[11,12]. The therapeutic potential of targeting adrenal
steroid synthesis to inhibit aldosterone production has
not been fully explored due to the lack of selective
aldosterone synthase inhibitors (ASIs).
Aldosterone synthase, which is encoded by the CYP11B2
gene, is highly expressed in adrenal gland glomerulosa cells
and is expressed at lower levels in other tissues [13,14].
Aldosterone synthase converts 11-deoxycorticosterone
(11-DOC) to aldosterone by sequential 11-β hydroxyl-
ation, 18-hydroxylation and 18-oxidation [15,16]. Selective
inhibition of aldosterone synthase could provide an
effective approach to decrease aldosterone production,
thus attenuating both receptor-mediated and non-genomic
deleterious consequences of aldosterone excess.
We report the in vitro and in vivo effects of aldosterone
synthase inhibition with LCI699 (4-[(5R)-dihydro-5H-
pyrrolo[1,2-c]imidazol-5-yl]-3-fluorobenzonitrile phosphate)
[17] in rats, non-human primates and humans. We
have characterized the enzymatic inhibition and species
specificity of LCI699 and have established the relative
selectivity of LCI699 for aldosterone synthase over 11β-
hydroxylase (encoded by the CYP11B1 gene), which
converts 11-deoxycortisol to cortisol and has 93% nucleo-
tide sequence identity with aldosterone synthase [18]. In
order to determine the therapeutic potential of an ASI, the
effects of LCI699 on cardiorenal damage and survival were
assessed in a double-transgenic (dTG) rat model with
ectopic overexpression of human renin and angiotensino-
gen and the results compared with those of the MRA
eplerenone. In healthy human subjects, LCI699 selectivelyinhibited aldosterone synthase at oral doses ≤ 1 mg daily,
but lost specificity above the 1 mg dose. Therefore LCI699
is no longer being developed for essential hypertension,
and is currently under development at higher, nonselective
doses for the treatment of Cushing’s syndrome [19].
Methods
In vitro enzyme inhibition
Experimental design
Cell lines and tissue samples Recombinant human cyto-
chrome P450 (CYP) 11B2 and CYP11B1 enzymes were
prepared from the cell lines V79-4 CYP11B2-adrenodoxin-
adrenodoxin reductase (AAR) #317 and V79-4 CYP11B1-
AAR #618, respectively [20]. Recombinant rat CYP11B2
and CYP11B1 enzymes were prepared similarly. All cell
lines were maintained in Dulbecco’s modified Eagle’s
medium supplemented with 10% fetal bovine serum,
0.5× antibiotic, 800 μg/mL geneticin and 250 μg/mL
hygromycin (double-selection medium; all from Invitrogen,
Carlsbad, CA, USA).
Rat adrenal homogenates were prepared from the
adrenal glands of male Sprague-Dawley (S-D) rats as
described previously [21]. Monkey CYB11B2 and CYB11B1
homogenates were prepared from the adrenal glands of
female cynomolgous monkeys. Monkey adrenal gland
tissue was minced and homogenized on ice in a glass
tissue grinder in 1 mL of ice-cold homogenization buffer
per 100 mg tissue (adding 2.7 mmol/L CaCl2 and one
ethylenediaminetetraacetic acid (EDTA)-free protease
inhibitor tablet per 50 mL buffer) [20]. The homoge-
nized material was centrifuged at 450 g for 5 min at
4°C, and the supernatant brought to a final glycerol
concentration of 5%, flash-frozen in liquid nitrogen,
and stored at −80°C until analysis. Aldosterone, cortisol
and corticosterone concentrations were quantified using
96-well plate assays (see Additional file 1).
CYP11B2 and CYP11B1 enzyme assays Human
CYP11B2 and CYP11B1 assays were performed as de-
scribed previously [20]. The rat and monkey assays were
conducted similarly, using 11-DOC as substrate.
Statistical analysis
Concentration–response curves for LCI699 were per-
formed at least three times (and two times for rat hom-
ogenate assay). Half-maximal inhibitory concentration
(IC50) values were derived using a non-linear least-squares
curve-fitting program (XLfit; ID Business Solutions Inc.,
Bridgewater, NJ, USA).
In vivo Ang-II- and ACTH-infusion models
Experimental design
Animal procedures All animal procedures were con-
ducted in accordance with an approved Novartis Animal
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the Care and Use of Laboratory Animals as described
previously [21]. Male S-D rats (~500 g) were purchased
from Taconic Farms (Germantown, NY, USA) and accli-
matized in the Novartis vivarium (12 h light/dark cycle;
72°F; 55% relative humidity) for at least 7 days before
being used in experiments. Rats were provided normal
chow (Harlan Teklad 8604) and water ad libitum except
for a partial fast before and during an experiment.
Male cynomolgus monkeys (Macaca fascicularis) were
selected for their cooperation and ability to sit comfort-
ably in chairs and were conditioned to remain in the
chairs for extended periods before the studies began. On
the day of the experiment, monkeys were removed from
their home cages with a pole/collar device (Primate
Products, Inc., Woodside, CA, USA), secured in their
restraining chairs, and transported to the quiet study
room. The monkeys remained in the chair for the dur-
ation of the experiment (up to 10 h), during which time
an enrichment and feeding regimen was followed.
Both rats and monkeys were surgically instrumented
with chronically indwelling femoral venous and arterial
catheters to allow intravenous administration of sub-
stances and repeated blood sampling. Details of the sur-
gical procedure are outlined in Additional file 1.
LCI699 formulation LCI699 solution was freshly pre-
pared (from powder) before each experiment. In the rat
models, LCI699 (free base) was first dissolved in
1.5 molar equivalents of 1 N HCl plus 10 parts of water
and then diluted in 3% cornstarch (1 mL/kg volume). In
the monkey model, LCI699 (phosphate salt) was dissolved
in water (1 mL/kg volume). LCI699 was administered by
oral (rat and monkey) or nasogastric gavage (monkey).
Compound doses in the monkey model are quoted as free
base equivalents.
Experimental protocol for rat models Study protocols
for the rat models of Ang-II- and ACTH-stimulated
aldosterone synthesis followed a published protocol [21].
For the Ang-II-infusion model, an initial loading dose
of 300 ng/kg angiotensin II (Ang II) was followed by
100 ng/kg/min intravenous (i.v.) infusion for 9 h. For the
ACTH-infusion model, the loading and infusion doses of
ACTH were 100 ng/kg and 30 ng/kg/min, respectively.
After 1 h of Ang II or ACTH infusion, a blood sample
was collected for determining the post-Ang II or ACTH
‘baseline’ (i.e., secretagogue-elevated) plasma aldosterone
and corticosterone concentrations. LCI699 was adminis-
tered at doses of 0.1, 0.3, 1 and 3 mg/kg in the Ang-II-
infusion model, and 1, 3, 10, 30 and 100 mg/kg in the
ACTH-infusion model. In both models, infusion continued
for a further 8 h. Blood samples were withdrawn in heparin
(final concentration 15 U/mL) from the arterial cannula at15 and 30 min, and 1, 2, 3, 4, 5, 6, 7, 8, and 24 h post-
dosing. Plasma aldosterone and cortisol were determined
by radioimmunoassay and LCI699 by liquid chromatog-
raphy separation coupled with tandem mass spectrometric
detection (LC-MS/MS) (see Additional file 1).
Experimental protocol for monkey model Six mon-
keys (4.9–8.8 kg) were selected and were divided into
two groups of three animals. Experiments were not ini-
tiated until after at least 2 weeks of recovery from the
catheter/vascular access port (VAP) surgeries. Thirty
minutes before the start of the experiment, a Huber
needle was inserted transdermally into the VAP for the
collection of blood samples and injection of ACTH.
Between samplings, catheters/VAPs were flushed with
saline and kept patent with 10 U/mL heparin. In all
cases, the total blood withdrawn did not exceed 1% of
body weight per week, and at least 1 week of recovery
was allowed between sequential experiments.
Blood samples (0.3 mL in 15 U/mL heparin) for base-
line pharmacokinetic and pharmacodynamic assessments
were collected at 0.5 h, 0.25 h and immediately before
dosing. LCI699 (5, 15, 50 or 150 μg/kg) or vehicle (water)
was administered followed 3 h later by ACTH(1–24)
(CortrosynW; Amphastar Pharmaceuticals, Inc., Rancho
Cucamonga, CA, USA) 3000 ng/kg i.v. in 0.1 mL/kg
(over ~2 min). The 3000 ng/kg dose of ACTH was de-
termined from a pilot dose–response experiment, which
showed a consistent and maximal stimulation of plasma
aldosterone and cortisol. Blood samples were collected
at 0.125, 0.25, 0.5, 0.75 and 1 h after ACTH injection to
assess the time course of plasma aldosterone and corti-
sol stimulation. Further blood samples were collected
up to 8 h and at 23.5 and 24 h after LCI699/vehicle
administration. Between the 8 h and 23.5 h collections,
the Huber needles were removed and the monkeys were
returned to their home cages. All instrumentation was
removed after the last sample at 24 h. Plasma aldoster-
one and cortisol were determined by radioimmunoassay
and LCI699 by LC-MS/MS (see Additional file 1).
Statistical analysis
All pharmacokinetic parameters were derived from con-
centration–time data by non-compartmental analyses
and were calculated using WinNonlin (Enterprise, Version
5.2; Pharsight Corporation, Palo Alto, CA, USA).
ACTH responses were defined as the peak plasma
aldosterone or cortisol concentration within 1 h after the
ACTH injection (i.e., between 3 and 4 h after LCI699
administration), expressed as a percentage of the cor-
responding monkey’s response in the vehicle control
experiment. Half-maximal effective dose (ED50) values
for the ACTH-stimulated responses were estimated by
linear regression of these individual percentage peak
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effective concentration (EC50) values were calculated in a
similar fashion by separate linear regression of the per-
centage peak responses with the logarithmic LCI699
plasma concentrations at 3 h and 4 h, and the mean 3-h
and 4-h values.
Student’s paired t-test was used to evaluate pairwise
comparisons of responses after LCI699 or vehicle in a
given monkey. Data and statistical analyses were con-
ducted with Microsoft Excel (Version 2007, Microsoft,
Redmond, WA, USA). All differences were considered
statistically significant at a two-sided P value ≤ 0.05.
Double-transgenic rat models
Experimental design
To determine the effects of inhibiting aldosterone syn-
thase in an experimental model of rapidly progressive
RAS-driven hypertension with cardiac and renal damage,
we used dTG rats overexpressing human renin and
angiotensinogen, as previously described [22]. dTG rats
are characterized by high circulating levels of human
renin, Ang II and aldosterone, left ventricular (LV)
hypertrophy, and rapidly progressive cardiac and renal
disease with moribundity or death occurring on average
by 2 months of age.
In order to study the effects of aldosterone inhibition on
survival in older dTG rats with established cardiorenal
disease, we modified the model by treating male dTG
rats during their developmental stage (3–8 weeks of
age) with the angiotensin-converting enzyme (ACE)
inhibitor enalapril. We determined that pre-treatment
of male dTG rats with enalapril at a dose of 10 mg/kg/day
(40 mg/L in drinking water) from 3 to 8 weeks of age pro-
longed median survival by approximately 4 months. These
rats developed progressive cardiac and renal impairment,
allowing evaluation of the effects of aldosterone synthase
inhibition with LCI699 in dTG rats with pre-established
cardiorenal disease and high mortality. A similar model
was recently reported in dTG rats by St-Jacques et al. [23].
dTG rats were bred from their respective single trans-
genic lines at Novartis under a license agreement with
the Max-Delbruck-Centrum fur Molekulare Medizin
(Berlin-Buch, Germany). Age-matched male S-D rats
were bred by Taconic Farms (Germantown, NY, USA).
This background strain for the dTG rats served as
healthy controls. Rats were maintained on a 12-h light/
dark cycle at 72°F with 55% relative humidity and were
provided normal food (Harlan Teklad 8604) and water
ad libitum.
Experimental rat protocols Rats were treated with
LCI699 (phosphate salt) dissolved in drinking water or
eplerenone in chow. LCI699 concentrations (ranging
from 12 to 400 mg/L) were adjusted for changes inwater consumption to achieve the targeted doses of
3–100 mg/kg/day. At the nominal doses of 3, 10, 30
and 100 mg/kg LCI699, the actual measured doses were
4 ± 0, 10 ± 1, 28 ± 3 and 65 ± 4 mg/kg, respectively.
Administration of LCI699 in drinking water dose-
dependently and proportionally increased total plasma
concentration of LCI699 from 58 nmol/L at the lowest
dose to 2000 nmol/L at the highest dose.
The maximum effective dose of eplerenone for pro-
longation of survival was 30 mg/kg, which was the dose
chosen to assess the effects of mineralocorticoid recep-
tor blockade on cardiorenal structure and function.
Two rats were excluded from all data analysis owing to
severe hematuria and moribundity on the scheduled
take-down day.
In studies in young dTG rats, water consumption was
measured and urine collected for renal biomarkers
24 hours before the terminal experiment. On the final
experimental day, rats were anesthetized to allow for
echocardiographic examination. A carotid artery was
then cannulated for direct recording of arterial pressure
and heart rate. Blood (aortic puncture) and organ/tissue
samples were collected, and the animal was euthanized.
In experiments with older dTG rats (treated with
enalapril for 5 weeks), urine collections and echocardio-
graphic examinations were conducted as above but sys-
tolic arterial pressure was estimated in conscious rats by
tail plethysmography (Model# 56-1, IITC Life Science
Inc., Woodland Hills, CA, USA) using appropriate tail
cuff sensors (B63), and restrainer (size 80), at a constant
chamber temperature of 30°C.
Echocardiographic images were acquired with a Vivid
7 (GE Healthcare, Milwaukee, WI, USA) instrument and
an M12L (GE Healthcare) linear probe (14 MHz) with
appropriate frame rates (M-mode: 164.8 frames per sec-
ond (fps); 2D mode: 210.3 fps; TDI mode: 365.5 fps).
Images were analyzed offline with EchoPAC™ Dimension
software (GE Healthcare).
In the survival studies, dTG rats were euthanized if
they became moribund. Moribundity was defined as a
decrease in body weight of ≥ 20% from “baseline” or two
consecutive days of observable hematuria. The study
endpoint was the age of the animal at death or at mori-
bundity requiring euthanization.
Sample processing for morphometric evaluation Hearts
were perfused in situ with KCl (50 mmol/L), which
quickly arrested the heart and depolarized the myocytes
allowing for a more standardized and reproducible
assessment of myocardial cell size. Hearts were fixed
in 10% formalin. Myocyte cross-sectional area was assessed
on sections cut at the mid-papillary level and stained with
1:100 FITC wheat-germ agglutinin (Vector Lab, catalog #
FL-1021). Digital images were taken from the LV free wall,
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Image analysis of round cells (~500 per heart) on cross-
section was performed to estimate mean cell size.
Sample processing for clinical chemistry Serum and
urinary electrolytes (Na+, K+, and Cl−) and creatinine and
blood urea nitrogen (BUN) were assessed with a Hitachi
917 chemistry analyzer. Urinary albumin concentration was
measured with a commercially available enzyme immuno-
assay (EIA) kit (catalog # A05102; SPI-BIO, Montigny Le
Bretonneux, France) according to the manufacturer’s
instructions. Plasma aldosterone and corticosterone con-
centrations and LCI699 concentrations were assessed as
previously described (also see Additional file 1).
Human pharmacokinetic–pharmacodynamic and safety
studies
Experimental design
Study population Healthy male volunteers, 18–45 years
of age and with a body mass index of 18–28 kg/m2 were
eligible for this study. Subjects had to be non-smokers
with normal hepatic and renal function for inclusion.
Subjects included in the multiple-dose phase of the study
had to have a normal cortisol stimulation test (cortisol >
580 nmol/L or > 21 μg/dL) on Day –2. All subjects pro-
vided informed written consent before participating in any
study procedures. The study was conducted at two centers
in the Netherlands and one in Germany and was approved
by the Independent Ethics Committee and/or Institutional
Review Board for each study center (Stichting Beoordeling
Ethiek Biomedisch Onderzoek, Assen, Netherlands; Ethics
Committee of the Land, Berlin, Germany) and was con-
ducted in accordance with Good Clinical Practice and
the ethical principles of the Declaration of Helsinki.
Study design This was a randomized, double-blind,
placebo-controlled, interwoven single- and multiple-
ascending-dose study. In the single-dose phase, five
cohorts of eight subjects each were enrolled. Each cohort
received one of five LCI699 doses (3, 10, 30, 100 or
200 mg) in ascending order. Subjects were randomized to
LCI699 or placebo in a 6:2 ratio. Assessments were made
throughout the treatment period, and at an end of study
assessment 7 days post-dose.
The multiple-dose phase involved four cohorts, each
of 18 subjects. After inhibition of the cortisol stimula-
tion test was observed with the first few subjects in the
10 mg multiple-dose cohort, the protocol was amended
to study lower doses of 0.5, 1 and 3 mg for the multiple-
dose phase. In each cohort, subjects were randomized
to once-daily doses of LCI699, placebo or the MRA
eplerenone 100 mg in a 12:3:3 ratio for 14 days. Subjects
were placed on a controlled sodium restricted diet from
the day before dosing until 72 h post-dose and werehoused at the study center for this period. Until Day 7,
the diet was ~50–60 mEq Na+/~50–60 mEq K+. On the
morning of Day 8, potassium in the diet was increased
to ~100 mEq. Based on urinary electrolyte values
obtained from placebo subjects on Day 7 and Day 14 re-
spectively, the actual diet was ~95 ± 63 mEq Na+/46 ±
12 mEq K+ for the first week and ~86 ± 42 mEq Na+/69 ±
25 mEq K+ for the second week.LCI699 formulation LCI699 (phosphate salt) was
provided as hard gelatin immediate-release capsules
(0.5, 5 and 50 mg) for oral administration.Pharmacokinetic assessments Blood samples for phar-
macokinetic assessment were obtained pre-dose and at
regular intervals up to 72 h post-dose in the single-dose
phase of the study. In the multiple-dose phase, blood
samples were taken on Day 1 and Day 14 at regular
intervals up to 36 and 72 h post-dose, respectively, and
pre-dose on Days 3, 4, 7 and 11. Blood samples (2 or 4 mL)
were collected into an EDTA containing tube, plasma
extracted and samples frozen at –70°C until analysis.
LCI699 concentrations in plasma were analyzed by LC-
MS/MS (see Additional file 1).Pharmacodynamic assessments Pharmacodynamic as-
sessments included the measurement of aldosterone,
plasma renin activity (PRA), cortisol and 11-deoxycortisol
during both phases of the study. In addition, ACTH and
11-DOC were measured during the multiple-dose phase.
During the single-dose phase, blood samples for pharma-
codynamic assessments were collected pre-dose and at
1, 2, 4, 8, 12 and 24 h post-dose. During the multiple-dose
phase, samples were collected pre-dose and at 1, 2, 4, 8
and 12 h post-dose on Days −1 (baseline), 1, 7, 8 and 14,
as well as pre-dose on Days 2 and 9, and at 24, 48 and
72 h after the final dose (i.e., on Days 15, 16 and 17). In
addition, subjects underwent a cortisol stimulation test on
Days –2, 6 and 13; An ACTH analog was injected 2 h
post-dose and blood samples were collected prior to, and
at 30 and 60 min after, the ACTH injection. Aldosterone
and PRA levels were measured by radioimmunoassay
and cortisol and 11-deoxycortisol levels by LC-MS/MS
(see Additional file 1).Safety and tolerability assessments All adverse events
were recorded during the study period. In addition, vital
signs and body weight were measured daily, while blood
hematologic and chemistry profiles, urinalysis, physical
condition and 12-lead electrocardiograms were moni-
tored regularly throughout the study.
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All subjects with quantifiable pharmacokinetic measure-
ments were included in the pharmacokinetic data analysis.
Pharmacokinetic parameters were analyzed separately for
the single- and multiple-dose phases and were determined
using non-compartmental analyses. A power model (area
under curve [AUC] or maximum plasma concentration
[Cmax] = α * Dose
β) was used to evaluate dose proportion-
ality of LCI699 exposure after single- and multiple-dose
administration [24].
All subjects with evaluable pharmacodynamic mea-
surements were included in the analysis, and data from
the two study phases were analyzed separately. An ana-
lysis of covariance (ANCOVA) with treatment as factor
and baseline value as covariate was performed to evaluate
changes from baseline in pharmacodynamic parameters at
each time point. Least-squares mean differences and asso-
ciated 95% CIs were calculated for comparison of LCI699
and eplerenone groups with placebo.
An analysis of variance (ANOVA) with treatment as the
classification factor was performed on orthostatic changes
(standing-supine) in pre-dose systolic blood pressure,
diastolic blood pressure, and heart rate measurements
for each of Days 1, 7, and 14 separately. Each LCI699
dose and eplerenone treatment were compared with the
placebo treatment (subjects pooled across all cohorts)
within the ANOVA framework.
An ANCOVA with treatment as the classification
factor and baseline as the covariate was performed on
change from baseline (Day 1 pre-dose) to Day 7 and
Day 14 for pre-dose supine and standing systolic blood
pressure (SBP), diastolic blood pressure (DBP), and
heart rate and for orthostatic changes (standing–
supine). Each LCI699 dose and the eplerenone treatment
were compared with the placebo treatment within the
ANCOVA framework.
Results
In vitro enzyme inhibition
LCI699 dose-dependently inhibited the activity of recombin-
ant human aldosterone synthase (IC50 = 0.7 nmol/L) with
3.6-fold selectivity over 11β-hydroxylase (IC50 = 2.5 nmol/L)
(Table 1). Lineweaver–Burk plots (Figure 1) showed that
LCI699 is a reversible competitive inhibitor of recombin-
ant human aldosterone synthase (Ki = 1.4 ± 0.2 nmol/L,
mean ± SEM) and, at higher concentrations, of
11β-hydroxylase (Ki = 2.4 ± 0.3 nmol/L).
In vitro enzymatic studies using rat recombinant
enzymes showed that LCI699 was approximately 230-fold
less potent at inhibiting rat aldosterone synthase than the
human enzyme (Table 1). Nevertheless, LCI699 had simi-
lar weak selectivity for recombinant rat aldosterone syn-
thase and 11β-hydroxylase (2.6-fold difference) compared
with that for the recombinant human enzymes.In monkey adrenal homogenates, the IC50 of LCI699
for aldosterone synthase was 17-fold higher than that
for the human recombinant enzyme, but was 67-fold
lower than the IC50 measured in rat adrenal homogenates.
Selectivity for aldosterone synthase over 11β-hydroxylase
was 5.2-fold in monkey adrenal homogenates.
In summary, the relative species rank order of LCI699
potency for inhibiting aldosterone synthase was human
>monkey > rat, whereas the 3- to 5-fold selectivity for
aldosterone synthase over 11β-hydroxylase was similar
across these species.Animal pharmacokinetic and pharmacodynamic studies
In vivo effects of LCI699 in rat and monkey models of
adrenal hormone stimulation
Pharmacokinetic data for LCI699 after single oral
administrations in rats (0.1–3 mg/kg in the Ang II model,
and 1–100 mg/kg in the ACTH model; Additional
file 2A–B) showed that LCI699 was rapidly absorbed
(time to maximum plasma concentration [tmax] 0.3–2.4 h)
with a terminal elimination half-life (t½) of 2–5 h. Over
the tested dose range, the pharmacokinetics of LCI699
were dose-proportional. Plasma protein binding was
low (35.9%).
The effects of LCI699 on aldosterone and corticosterone
synthesis were assessed in two in vivo rat models. Adrenal
hormones were stimulated with either exogenous Ang II or
ACTH. Oral administration of LCI699 dose-dependently
inhibited the increase in plasma aldosterone concentrations
stimulated by Ang II or ACTH, with an apparent plateau
effect above 1 mg/kg for Ang II stimulation and 10 mg/kg
for ACTH stimulation. Maximal reductions in plasma
aldosterone from baseline of 80% were reached approxi-
mately 2 h after dosing (Additional file 3A–B).
Dose–response relationships for LCI699 in the two rat
models are shown in Figure 2A. The ED50 for inhibiting
Ang-II-stimulated aldosterone response was 0.6 mg/kg.
The corresponding half-maximal effective plasma LCI699
concentration (EC50 = 127 nmol/L; Figure 2B) was similar
to the in vitro IC50 (160 nmol/L) for inhibiting rat re-
combinant aldosterone synthase. In the ACTH-infusion
model, the LCI699 ED50 and EC50 values for inhibiting
stimulated aldosterone (1.1 mg/kg; 771 nmol/L) and
corticosterone (73 mg/kg; 36 μmol/L) responses resulted
in dose and exposure selectivity ratios of 65 and
47, respectively (results not shown).Monkey ACTH-stimulation model
Pharmacokinetic data for LCI699 after single oral drug
administrations in monkeys (15–150 μg/kg) showed that
LCI699 was rapidly absorbed (tmax 0.9–3.5 h), with a t½ of
1–2 h (Additional file 2C) and dose-proportional pharma-
cokinetics. Plasma protein binding was low (26.6%).







Recombinant human enzyme 0.7 ± 0.01 (6) 2.5 ± 0.1 (4) 3.6
Recombinant rat enzyme 160 ± 9 (3) 410 ± 5 (3) 2.6
Rat adrenal homogenate 802 (2) 3045 (2) 3.8
Monkey adrenal homogenate 12 ± 1 (6) 62 ± 5 (6) 5.2
Table shows selectivity ratios for LCI699 for inhibition of aldosterone synthase (CYP11B2) over 11β-hydroxylase (CYP11B1). All values are mean ± SEM (n) except
for rat adrenal homogenate where only mean values from two experiments are presented.
aSelectivity ratio is defined as the ratio of IC50 values obtained in the CYP11B2 and CYP11B1 assays.
CYP, cytochrome P450; IC50, half maximal inhibitory concentration.
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prior to ACTH injection dose-dependently inhibited
the ACTH-stimulated increase in plasma aldosterone
concentration (Additional file 3C). The highest LCI699
dose (150 μg/kg) caused approximately a 90% decrease
in response compared with the vehicle control. Plasma
aldosterone levels returned to baseline 24 h after
dosing. No significant inhibition of ACTH-stimulated
cortisol synthesis was observed with any dose of LCI699
tested (5–150 μg/kg), indicating in vivo selectivity of
LCI699 for inhibition of aldosterone over cortisol syn-
thesis in the monkey (data not shown).
The estimated LCI699 ED50 for inhibition of ACTH-
stimulated plasma aldosterone was 13 μg/kg (Figure 2C).
Plasma concentrations of LCI699 below the assay limit of
quantification prevented calculation of an accurate EC50
value; however, it could be estimated at less than 1 nmol/L,
considerably lower than the in vitro IC50 for inhibition of
aldosterone synthase in monkey adrenal homogenates.Animal disease model studies
Development of hyperaldosteronism and cardiorenal disease
in young dTG rats
Compared with age- and strain-matched control S-D rats,
dTG rats had elevated plasma aldosterone concentrations
(8-fold) and 24 h urinary aldosterone excretion (15-fold)
(Figure 3A–B). Plasma corticosterone was not significantly
different between dTG rats and control S-D rats (data not
shown). Serum potassium was lower in dTG rats com-
pared with S-D rats (Figure 3C–D) consistent with hyper-
aldosteronism. Beginning at 5 weeks of age, dTG rats
developed progressive hypertension, LV hypertrophy, im-
paired cardiac function (Figure 3E–H), and ventricular
arrhythmias, culminating in death between 7 and 9 weeks
of age. dTG rats were polydipsic and polyuric with a
4-fold higher urine volume flow compared with S-D rats
(Figure 3I). Impaired renal function also developed in
dTG rats, as evidenced by elevated serum BUN levels and
increased urinary albumin excretion (Figure 3J–K).Effects of LCI699 and eplerenone on adrenal hormone,
cardiac and renal abnormalities in dTG rats
Treatment with LCI699 dose-dependently normalized
plasma aldosterone concentration (EC50 = 50 nmol/L;
P < 0.05) and also reduced urinary aldosterone and
corticosterone excretion (Figure 3A–B). In contrast,
eplerenone (30 mg/kg/day, a dose shown to maximally
prolong survival [Figure 4, inset]) had no effect on
plasma aldosterone of dTG rats and significantly in-
creased (P < 0.05) urinary aldosterone excretion (data
not shown), confirming its biologic activity as an
MRA. LCI699 corrected serum potassium in a dose-
dependent manner (Figure 3C) whereas eplerenone
had no effect.
Significant differences in cardiovascular effects were
observed between LCI699 and eplerenone. Although
LCI699 tended to decrease mean arterial pressure
slightly, neither LCI699 nor eplerenone normalized
arterial pressure (Figure 3E). LCI699 dose-dependently
increased fractional LV shortening, normalized LV iso-
volumic relaxation time to RR (IVRT/RR) ratio and
myocardial cell size (P < 0.05; Figure 3F–H) and re-
duced LV weight (not shown). In contrast, eplerenone
(30 mg/kg) had no significant effect on either fractional
shortening or IVRT/RR ratio, reduced but did not
normalize myocardial cell size (Figure 3E–H) and had
no effect on LV weight (data not shown).
Significant differences in renal effects were also ob-
served between LCI699 and eplerenone. Treatment of
dTG rats with LCI699 dose-dependently normalized
BUN levels and urinary albumin excretion, water intake
(data not shown) and urine output (P < 0.05). In con-
trast, eplerenone had no significant effect on BUN or
urine output, while urinary albumin excretion was
slightly increased, P < 0.05 vs vehicle) (Figure 3I–L).
Measures of LV cell size and weight, kidney weight, LV
function (systolic and diastolic) and renal function, were
highly correlated with plasma aldosterone concentra-
tions for pooled data from all five groups of dTG rats
(controls and LCI699-treated; Additional file 4).
Figure 1 Structure of LCI699 (A) and in vitro inhibition of (B)
aldosterone synthase (CYP11B2) and (C) 11β-hydroxylase
(CYP11B1). (A) shows LCI699 phosphate salt. (B) shows Lineweaver–
Burk plots of inhibition by LCI699 of human recombinant aldosterone
synthase (CYP11B2) and 11β-hydroxylase (CYP11B1). Intersection of
lines indicates competitive inhibition of both enzymes by LCI699
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Figure 2 Effect of LCI699 on Ang-II- and ACTH-stimulated
hormone release in rat and monkey in vivo models.
(A) Dose–response plot and (B) exposure–response plot (8-h
time-weighted average concentrations as percentage of baseline
values) of effect of LCI699 on Ang-II stimulated plasma aldosterone and
adrenocorticotropic hormone (ACTH)-stimulated plasma aldosterone
and corticosterone in rats and (C) dose–response plot of effect
of LCI699 on ACTH-stimulated plasma aldosterone and cortisol
concentrations in monkeys. Values are mean ± SEM. Number of
evaluable animals was n = 3 per dose group.
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established cardiorenal disease
Aldosterone synthase inhibition significantly prolonged
survival in dTG rats without established cardiorenal dis-
ease. In the control group, 9 of 10 dTG rats died by
8.4 weeks of age. LCI699 prolonged survival in a dose-
dependent manner (P < 0.01) starting at 10 mg/kg/day
(Figure 4A). Eplerenone also significantly prolonged
Figure 3 (See legend on next page.)
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Figure 3 Effect of LCI699 and eplerenone on adrenal hormones, serum electrolytes, cardiac and renal parameters in dTG rats. (A)
Plasma aldosterone concentrations (PAC); (B) urinary aldosterone excretion (UAldoE); (C) serum potassium; (D) serum sodium; (E) mean arterial
pressure (MAP); (F) LV fractional shortening (FS); (G) LV isovolumic relaxation time (IVRT) as a percentage of R-R interval; (H) LV myocardial cell
size; (I) 24-h urine volume (V); (J) 24-h urinary albumin excretion (UAE); (K) blood urea nitrogen (BUN) and (L) creatinine clearance (CCr). Values
are shown for double-transgenic (dTG) rats (triangle), dTG rats treated with LCI699 (3, 10, 30 or 100 mg/kg/day in drinking water) or eplerenone
(Epl, 30 mg/kg/day in chow) from 3 to 7 weeks of age (square) and in control Sprague-Dawley (S-D) rats (circle). Eplerenone vehicle controls are
depicted separately from LCI699 vehicle controls. Measurements were taken at 7 weeks of age. Values are mean ± SEM. Number of evaluable animals
was n = 6 per dose group, with the exception of S-D rat controls (n = 11). *P < 0.05 vs dTG rats. †P < 0.05 vs S-D rats.
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no statistically significant difference between the dose-
survival curves for eplerenone (3 –300 mg/kg/day) and
LCI699 (1–100 mg/kg/day) (P = 0.2). However, eplere-
none appeared to affect early deaths less than LCI699,
and the maximum median survival time with eplerenone
(8.4 weeks) was less than that observed with LCI699
(9.5 weeks; Figure 4 inset). Although the precise cause of
death in the dTG rats could not be ascertained,
40% required euthanasia owing to moribundity and
60% died unexpectedly and suddenly. There were no sig-
nificant differences in mode of death between control dTG
rats and those treated with either LCI699 or eplerenone.
LCI699 (30 mg/kg/day in drinking water; n = 7) also
prolonged survival in dTG rats with established cardior-
enal disease. The disease model employed dTG male rats
24 weeks of age pre-treated with the ACE inhibitor enal-
april from 3 to 8 weeks of age to reduce early post-natal
mortality. Figure 4B shows Kaplan–Meier curves for the
control dTG group and the dTG group treated with
LCI699. In all, 4 of 8 control dTG rats died by 29 weeks
of age and 7 of 8 died by 38 weeks of age. LCI699 treat-
ment tended to prolong median survival by 23 weeks
(P = 0.07). Whereas all of the control dTG rats died
unexpectedly and suddenly, only two of the seven LCI699-
treated rats died suddenly.
Human pharmacokinetic and pharmacodynamic studies
Subjects
Ninety-nine healthy male volunteers were randomized
and received LCI699 or placebo; 37 in the single-dose
phase and 62 in the multiple-dose phase. Demographic
characteristics were similar across treatment groups.
Mean ages were 21–31 years in the single-dose groups
and 32–36 years in the multiple-dose groups, and almost
all subjects (96%) were Caucasian. Baseline characteris-
tics of subjects who entered the multiple-dose phase are
shown in Table 2.
Thirteen subjects were discontinued from the study
during the multiple-dose phase. All five subjects receiving
LCI699 10 mg in the multiple-dose cohort were discontin-
ued from the study (two after 10 doses due to an abnormal
ACTH stimulation test as pre-specified in the protocol,
and three after three doses for safety precautions based onresults of the ACTH test). No additional subjects were
enrolled in the 10 mg cohort and because of this proto-
col change three subjects in the 10 mg cohort who were
receiving eplerenone (n = 1) or placebo (n = 2) were also
discontinued. Five subjects in the 3 mg cohort (three
receiving LCI699 3 mg, one receiving eplerenone and
one receiving placebo) were discontinued after nine or
10 doses (as per protocol) due to changes in body
weight and vital signs (> 2 kg decrease in body weight
and > 20 bpm increase in heart rate [HR] upon standing).
The three subjects receiving LCI699 3 mg also had plasma
sodium levels < 135 mEq/L at the time of discontinuation,
which returned to > 135 mEq/L within 1 to 2 days. No
subjects were discontinued in the LCI699 1 mg cohort.
Safety and tolerability
LCI699 was well tolerated. Adverse events reported
with single LCI699 doses up to 200 mg were all mild in
intensity except for one event of postural dizziness,
which was of moderate intensity. Headache and dizzi-
ness (without hypotension) were the most common
events during the single-dose phase, and there was no
dose-dependence of either the frequency or severity of
reported adverse events.
During the multiple-dose phase of the study, only
one adverse event (abnormal ACTH-stimulation test
with LCI699 10 mg) was considered severe owing to
the extent and duration of cortisol suppression. How-
ever, the subject showed no signs or symptoms of adrenal
insufficiency or hypotension. The frequency of minor
adverse events with LCI699 (headache, dizziness and
fatigue) was similar to that for eplerenone and placebo,
and showed no dose-dependence.
Multiple-dose treatment with LCI699 3 mg was asso-
ciated with pre-specified markers of hypoaldosteronism
in three subjects who were discontinued as per proto-
col; these effects included mild hyponatremia (plasma
sodium concentration < 135 mmol/L), postural tachy-
cardia and decreased body weight (> 2 kg). There were
no instances of hypotension with LCI699 at the 3 mg
dose. Two other subjects in this cohort (one receiving
eplerenone and one receiving placebo) also exhibited
postural tachycardia and weight loss, and were discon-
tinued as per protocol.
Figure 4 (See legend on next page.)
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Figure 4 Effect of LCI699 on survival in young dTG rats and older dTG rats with established cardiorenal disease. (A) Kaplan–Meier
survival curves for young, male double-transgenic (dTG) rats (control) and dTG rats treated with LCI699 (3, 30 or 100 mg/kg/day) or eplerenone
(30 mg/kg/day) in drinking water from 3 to 8 weeks of age. An additional group was treated continuously with 30 mg/kg/day for the duration of
the study. Inset shows dose–median survival curves for LCI699 and eplerenone. (B) Kaplan–Meier survival curves for older male dTG rats with
established cardiorenal disease who were pre-treated with enalapril (10 mg/kg/day in drinking water) from 3 to 8 weeks of age to slow the
progression of disease. At 24 weeks of age, dTG rats had developed cardiorenal disease and were randomized to a control group (n = 8) or an
LCI699 treatment group (30 mg/kg/day in drinking water) until moribundity or death. LCI699 prolonged survival in older dTG rats with established
cardiorenal disease.
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Mean plasma concentration–time profiles for LCI699
0.5–3 mg on Day 14 following once-daily oral adminis-
tration for 14 days are shown in Figure 5. LCI699 was
rapidly absorbed with Cmax reached ~1 h after dosing
(mean tmax, 1.00–1.25 h). The t½ of LCI699 was about
4 h after both single and multiple doses (mean t½
3.4–4.8 h across doses). Consistent with the relatively
short half-life of LCI699, trough plasma concentrations
reached steady state on Day 2, and the ratio of AUC
values on Day 14 and Day 1 showed no significant accu-
mulation of LCI699 (accumulation index 0.85–1.32).
Plasma protein binding of LCI699 was low (26.6%), simi-
lar to that observed in rats and monkeys.
Plasma exposure to LCI699 was approximately dose-
proportional over the dose range of 0.5–3 mg. Based on
multiple-dose data, the exponent β was 1.13 (90% CI,
1.00–1.25) for AUC0–24 and 1.16 (90% CI, 1.07–1.26) for
Cmax, indicating minimal deviation from true dose-
proportionality.
Evaluation of higher LCI699 doses up to 200 mg in
the single-dose phase of the study showed similar values
to the lower doses for t½ (~4 h) and tmax (~1 h). Over
the dose range 3–200 mg, LCI699 AUC0–24 exhibited an
exponent β of 1.29 (90% CI, 1.24–1.34; Additional file 5).Table 2 Baseline characteristics of healthy subjects (human st
Parameter LCI699 0.5 mg LCI699 1
n = 12 n = 12
Age, years 33.0 ± 6.0 32.1 ± 7
Body weight, kg 80.5 ± 6.1 76.1 ± 6
Supine heart rate, bpm 57 ± 5 63 ± 1
Supine blood pressure, mmHg 128/75 ± 8/7 124/73 ± 1
Plasma aldosterone, pg/mL 204.8 ± 78.7 186.4 ± 7
Plasma cortisol, ng/mL 120.5 ± 35.4 113.5 ± 2
Plasma ACTH, pg/mL 21.9 ± 6.9 26.0 ± 9
Plasma renin activity, ng/mL/h 1.24 ± 0.59 1.03 ± 0
Plasma sodium, mmol/L 140.8 ± 1.4 140.9 ± 1
Plasma potassium, mmol/L 4.5 ± 0.3 4.3 ± 0
Serum creatinine, μmol/L 94.5 ± 6.5 93.1 ± 1
Blood glucose, mmol/L 4.9 ± 0.5 4.9 ± 0
Values are mean ± SD unless otherwise stated.Pharmacodynamic effects of aldosterone synthase
inhibition: single-dose phase
Plasma and urinary aldosterone Single doses of LCI699
(3–200 mg) reduced plasma aldosterone concentration
2–24 h post-dose compared with placebo, with a max-
imal reduction of 60–78% from baseline at 12 h. LCI699
at these doses also reduced urinary aldosterone concen-
tration by 68–81% from baseline. There was no appar-
ent pattern of dose-dependence for either parameter
within this dose range, indicating that the maximum
effect was achieved at the 3 mg dose (results not shown).
Plasma and urinary cortisol LCI699 at doses of
3–100 mg did not significantly alter plasma cortisol; a
single dose of LCI699 200 mg caused a 19% decrease in
plasma cortisol 24 h post-dose (P = 0.029 vs placebo).
Significant reductions in 24-h urinary cortisol (34–42%)
were observed following single LCI699 doses of 30, 100
or 200 mg (vs 33% increase with placebo relative to
time-matched baseline; P ≤ 0.001), but with no clear
dose-dependence (results not shown).
Cortisol precursor Levels of the cortisol precursor
11-deoxycortisol increased with LCI699 at doses ≥ 100 mg
(942% and 584% with 100 mg and 200 mg, respectively;udy, multiple-dose phase)
mg LCI699 3 mg Eplerenone Placebo
n = 12 n = 10 n = 11
.2 34.2 ± 8.1 32.5 ± 5.2 35.8 ± 7.8
.2 76.8 ± 6.9 79.2 ± 6.0 82.8 ± 8.6
0 61 ± 5 62 ± 9 64 ± 8
1/8 123/75 ± 8/4 124/73 ± 9/6 124/74 ± 9/6
4.5 236.1 ± 85.6 244.9 ± 80.3 224.2 ± 83.5
8.2 112.9 ± 34.7 121.6 ± 46.1 103.4 ± 46.7
.6 30.7 ± 16.6 26.8 ± 14.1 22.1 ± 14.6
.65 1.00 ± 0.32 1.83 ± 1.36 1.30 ± 1.04
.2 140.8 ± 1.4 141.2 ± 1.3 140.9 ± 2.1
.2 4.5 ± 0.1 4.3 ± 0.3 4.3 ± 0.3
0.0 91.5 ± 6.3 90.6 ± 6.9 92.1 ± 4.4
.3 5.2 ± 0.5 5.2 ± 0.5 4.9 ± 0.7
Figure 5 Pharmacokinetic profile of LCI699 following once-
daily oral administration in humans. Plasma concentration–time
profile for LCI699 (mg dose of phosphate salt) on Day 14 following
once-daily oral administration in healthy human volunteers for
14 days. Values are mean ± SD. Number of evaluable subjects for
LCI699 0.5, 1 and 3 mg were n = 12, 12 and 9 respectively.
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11-β hydroxylase (results not shown).
Given the lack of dose-dependence in effects of LCI699
on aldosterone and observed effect on cortisol synthesis
with single doses of LCI699 ≥ 30 mg, the multiple-dose
phase was designed to evaluate doses of 0.5–10 mg.
Pharmacodynamic effects of aldosterone synthase
inhibition: multiple-dose phase
Plasma and urinary aldosterone Compared with the
small increase (37%) in plasma aldosterone concentra-
tion observed with placebo from time-matched baseline
(Day −1), LCI699 reduced plasma aldosterone concentra-
tion at 12 h on Day 1 (0.5 mg, –49%; 1 mg, –47%; 3 mg,
–63%; all P < 0.001 vs placebo); plasma aldosterone con-
centrations returned to baseline after 24 h (Figure 6A). No
further reduction in plasma aldosterone was observed fol-
lowing the 10 mg dose of LCI699 (data not shown). On
Days 7 and 14, LCI699 (0.5–3 mg) also reduced plasma
aldosterone from pre-dose baseline levels (Figure 6B–C).
Mean pre-dose plasma aldosterone levels increased,
however, from Day 1 to Day 14 during multiple-dose
administration of LCI699 (1 mg and 3 mg) from
400–502 pmol/L (144–181 pg/mL) on Day 1 to 458–719
pmol/L (165–259 pg/mL) on Day 7 and 580–813 pmol/L
(209–293 pg/mL) on Day 14. This was due to an increase
in aldosterone occurring at some time during the 12–24 h
post-dose nocturnal period (not investigated). Following
the last dose of LCI699 3 mg on Day 14, plasma aldoster-
one levels showed a rebound (peak increase at 48 h post-
dose) that continued during the post-treatment washout
phase (72 h after the final 3 mg dose; Figure 6C).
On Day 1, all three doses of LCI699 reduced 24 h urinary
aldosterone levels from baseline (0.5 mg, –39%; 1 mg,
–39%; 3 mg, –66%; all P < 0.001 vs placebo; Figure 6A).
On Day 7, the changes in 24 h urinary aldosterone levelswith LCI699 were diminished (1 mg, −12%; 3 mg, −44%)
relative to Day 1 and were significantly different from
placebo only for the 3 mg dose (Figure 6B). On Day 14,
reductions in 24 h urinary aldosterone following LCI699
administration showed little difference compared with
placebo except at the 3 mg dose (Figure 6C).
On Day 1, eplerenone 100 mg had no effect on plasma
aldosterone concentration, but increased 24 hour urinary
aldosterone by 34% (P < 0.001 vs placebo). On Days 7 and
14, eplerenone 100 mg significantly increased both plasma
aldosterone (46% on Day 7 and 63% on Day 14) and 24 h
urinary aldosterone levels (118% and 161%, on Days 7 and
14, respectively) (P < 0.001 vs placebo for all analyses).
Plasma and urinary cortisol LCI699 at doses of
0.5–3 mg had no significant effect on plasma or 24 h
urinary cortisol on Day 1, 7 or 14 (data not shown; see
Additional file 6 for Day 1). On Day 7, one subject
treated with LCI699 10 mg showed a large (> 70%)
reduction in 24 h urinary cortisol, while the second
subject showed no change.
Aldosterone and cortisol precursors Baseline trough
plasma concentrations of the aldosterone precursor,
11-DOC, were near the lower limit of quantification
(151 pmol/L [50 pg/mL]) across the groups on Day 1.
While there was no change in trough 11-DOC levels on
Day 7 after aldosterone synthase inhibition with
LCI699 0.5 or 1 mg, LCI699 3 mg led to a 228%
increase in 11-DOC levels from baseline (P < 0.001 vs
placebo; data not shown).
Without ACTH stimulation, an increase in cortisol
precursor (11-deoxycortisol) was observed at LCI699
doses ≥ 3 mg, although only the 10 mg dose was statisti-
cally significant. LCI699 10 mg was associated with
increases in Day 6 pre-dose plasma concentrations of
the cortisol precursor, 11-deoxycortisol of 508% from
baseline vs −16.5% with placebo (P < 0.001). Consistent
with this, no compensatory increases in trough or peak
ACTH levels were observed at doses ≤ 3 mg although
LCI699 10 mg increased pre-dose ACTH levels com-
pared with baseline by 193% (P < 0.001 vs placebo). Pre-
dose plasma ACTH measurements on Day 6 showed small
decreases from baseline levels with placebo (−12.3%) and
with LCI699 0.5–3 mg (0.5 mg, −14.5%; 1 mg, −31.4%;
3 mg, −15.6%), which did not differ significantly from
placebo.
ACTH stimulation test: aldosterone and cortisol The
ACTH stimulation test was performed 2 h post-LCI699
dose at the observed tmax. For ACTH-stimulated aldos-
terone levels (Figure 7A), LCI699 0.5–3 mg resulted in
peak inhibition of 41–64% from baseline (Day −2) on
Day 6 (vs 7% reduction with placebo; P < 0.001). By
Figure 6 Effect of LCI699 on plasma and urinary aldosterone concentrations (human study, multiple-dose phase). Mean plasma aldosterone
concentrations and percentage change in 24-hour urinary aldosterone from time-matched baseline on (A) Day 1, (B) Day 7 and (C) Day 14 of
once-daily treatment with LCI699 (0.5, 1 or 3 mg), eplerenone (100 mg) or placebo in healthy human volunteers. Values are mean ± SEM. Number of
evaluable subjects for LCI699 0.5, 1, 3 mg, eplerenone and placebo were (plasma) n = 12, 12, 12, 10 and 11 respectively, and (urine) n = 12, 9, 11, 9, 11.
*P < 0.05, ‡P < 0.001 vs placebo.
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Figure 7 Dose- and time-dependent effects of LCI699 on ACTH-stimulated aldosterone, cortisol and precursors (human study,
multiple-dose phase). Mean plasma concentrations of (A) aldosterone, (B) cortisol, (C) the aldosterone precursor 11-deoxycorticosterone (11-DOC),
and (D) the cortisol precursor 11-deoxycortisol, at 0, 30 and 60 min after adrenocorticotropic hormone (ACTH) administration at baseline (Day –2) and
on Days 6 and 13 of once-daily treatment with LCI699 (0.5, 1 or 3 mg), eplerenone (100 mg) or placebo in healthy human volunteers. Values are means.
Number of evaluable subjects for LCI699 0.5, 1, 3 mg, eplerenone and placebo were (Day -2 and 6) n = 12, 12, 12, 10 and 9 respectively, and (Day 13)
n = 12, 12, 9, 8 and 8 respectively. *P < 0.05, †P < 0.01, ‡P < 0.001 vs placebo.
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progressive increase in pre-ACTH aldosterone levels
2 h post-dose (increase vs Day −2 pre-ACTH levels; Day
6, 29%; P ≤ 0.01 vs placebo) (Figure 7A). In eplerenone-
treated subjects, ACTH stimulation on Day 6 resulted in a
63% increase in peak aldosterone levels.
LCI699 3 mg reduced ACTH-stimulated cortisol levels
on Day 6 (peak 22% reduction from baseline; P < 0.05 vs
placebo) (Figure 7B), whereas lower doses had no signifi-
cant effect (LCI699 0.5 mg, peak 1.8% reduction from
baseline; 1 mg, 11%). LCI699 10 mg further suppressed
ACTH-stimulated cortisol (P < 0.05 vs placebo) on Days
6 and 10, which reversed completely 4–9 days after dis-
continuing LCI699.
ACTH stimulation test: precursors of aldosterone
and cortisol synthesis LCI699 1 mg and 3 mg increased
ACTH-stimulated levels of the aldosterone precursor
11-DOC on Day 6 (maximal increases from baseline
95% and 407%, respectively) (Figure 7C). LCI699 0.5 mg
and eplerenone had no significant effect on ACTH-
stimulated 11-DOC levels. Consistent with the time-
dependent effects of LCI699 on aldosterone synthesis,
increases in ACTH-stimulated 11-DOC levels with
LCI699 1 mg and 3 mg were larger on Day 13 than
Day 6 (809% and 168%, respectively; Figure 7C).LCI699 3 mg also increased ACTH-stimulated levels of
the cortisol precursor 11-deoxycortisol on Day 6 (peak
82% increase from baseline; P < 0.001 vs placebo), with
a larger effect on Day 13 (peak 114% increase; P < 0.001;
Figure 7D). Eplerenone and lower doses of LCI699 had
no significant effect on cortisol precursors on Day 6 or
Day 13.
Plasma and urinary sodium and potassium
Aldosterone synthase inhibition with LCI699 induced a
rapid natriuresis on Day 1 of treatment (Table 3). The
natriuretic effect of LCI699 0.5 mg was similar to that
observed with eplerenone 100 mg and significantly
greater than that with placebo. LCI699 tended to de-
crease plasma sodium slightly (2–4 mmol/L) after 6 days’
administration of the 3 mg dose. In six LCI699-treated sub-
jects, plasma sodium levels were at or below 135 mmol/L
(two and four subjects receiving LCI699 0.5 mg and 3 mg,
respectively); there were no such changes observed in
subjects receiving eplerenone or placebo. No further
changes in sodium excretion were observed with LCI699
and eplerenone compared with placebo on Day 7 or 14,
indicating that a steady-state sodium balance was achieved
by Day 7.
There was a slight increase in plasma potassium
with LCI699 3 mg, on Day 1 (+0.40 mEq/L), Day 7
Table 3 Effect of LCI699 on plasma and urinary sodium and potassium (human study, multiple-dose phase)
LCI699 0.5 mg LCI699 1 mg LCI699 3 mg Eplerenone Placebo
n Mean n Mean n Mean n Mean n Mean
Plasma sodium, mEq/L
Baseline 12 139.3 12 140.1 12 140.6 10 139.9 11 139.6
Δ Day2a 12 +0.23 12 −0.59 12 −0.73* 10 −0.64 11 +0.26
Δ Day7b 12 −1.71‡ 12 −0.11 12 −2.87‡ 10 +0.31 11 +0.41
Δ Day14c 12 +0.41 12 −0.01 12 −0.45 10 −0.07 11 +0.35
Plasma potassium, mEq/L
Baseline 12 4.19 12 4.03 12 4.13 10 3.97 11 4.14
Δ Day2a 12 +0.20 12 +0.08 12 +0.40‡ 10 +0.08 11 0.00
Δ Day7b 12 +0.25‡ 12 +0.12* 12 +0.28‡ 10 −0.02 11 −0.05
Δ Day14c 12 +0.05 12 −0.06 12 +0.22* 10 −0.09 11 −0.06
Urinary sodium, mEq/24 h
Baseline 12 52.3 9 109.3 11 60.7 9 66.5 11 70.1
Δ Day 1a 12 +45.2† 9 +76.3‡ 11 +64.0‡ 9 +53.8‡ 11 +5.6
Δ Day 7b 12 +3.6 9 +44.0 11 +22.2 9 +16.2 11 +16.7
Δ Day 14c 12 −25.5 12 −3.6 12 −17.2 10 −24.0 9 −12.2
Urinary potassium, mEq/24 h
Baseline 12 38.7 9 42.5 11 49.1 9 46.4 11 44.8
Δ Day 1a 12 +9.2 9 +9.7 11 +2.9 9 +5.2 11 +8.6
Δ Day 7b 12 +12.8 9 +17.4* 11 +12.2 9 +6.4 11 +1.6
Δ Day 14c 12 +20.2 12 +4.2 12 +37.6* 10 +3.7 9 +17.5
aΔ values are comparisons of Day 1/Day 2–baseline (Day −1); bΔ values are comparisons of Day 7– baseline (Day −1); cΔ values are comparisons of Day 14– Day 7.
Mean changes (last observation carried forward) were derived from an analysis of covariance model with baseline value as a covariate. Based on urinary
electrolyte values obtained from placebo subjects on Day 7 and Day 14 respectively, the actual diet was ~95 ± 63 mEq Na+/46 ± 12 mEq K+ for the first week
and ~86 ± 42 mEq Na+/69 ± 25 mEq K+ for the second week.
*P < 0.05, †P < 0.01, ‡P < 0.001 vs placebo.
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and a small increase in urinary potassium excretion on
Day 14 (+37.6 mEq/24 h); changes that were not observed
in the other groups.
Plasma renin activity
Aldosterone synthase inhibition with LCI699 led to
increases in PRA, reflecting RAS counter-regulation
(Figure 8). Baseline PRA ranged from 0.65 to 1.83 ng/mL/h
across treatment groups, indicating mild stimulation of
RAS activity likely due to sodium restriction. All doses
of LCI699 significantly increased PRA compared with
placebo on Day 7 (Figure 8). The increase in PRA from
baseline with LCI699 0.5 mg (106%) was similar to that
observed with eplerenone 100 mg (92%), while larger
increases were observed with LCI699 1 mg (277%) and
3 mg (377%). Significant increases in PRA compared with
baseline were also observed with all doses of LCI699 on
Day 14 (130%, 327% and 238% increases with LCI699
0.5, 1 and 3 mg, respectively) and persisted for 72 h after
the last 3 mg dose. Compared with the effect of LCI699,
the increase in PRA with eplerenone on Day 14 was
130%, and returned toward baseline 48 h post-dose.Blood pressure, heart rate and other laboratory parameters
Compared with placebo, no consistent changes in supine
systolic or diastolic blood pressure or in heart rate were
observed following single or multiple doses of LCI699
or eplerenone (not shown). There were no significant
changes in ECG, urinalysis or in hematologic, hepatic or
other laboratory parameters.
Discussion
This is the first report of the effects of pharmacologic
inhibition of aldosterone synthase in healthy human
subjects. Results obtained with the ASI LCI699 indi-
cate that the hormonal and renal effects of blocking
the aldosterone pathway in healthy animals translate to
humans. In healthy volunteers, once-daily oral dosing
with LCI699 0.5 mg selectively reduced plasma and
urinary aldosterone, which was associated with natri-
uresis and an increase in PRA. LCI699 prolonged
survival in a rat disease model induced by ectopic over-
expression of human renin and angiotensinogen, and
was more effective than the MRA eplerenone in pre-
venting cardiac and renal damage. These results sup-
port the therapeutic potential of inhibiting aldosterone
Figure 8 Effects of LCI699 on plasma renin activity (PRA)
(human study, multiple-dose phase). Percentage change in PRA
from time-matched baseline during once-daily treatment with
LCI699 (0.5, 1 or 3 mg), eplerenone (100 mg) or placebo for 14 days
in healthy human volunteers, and at 24, 48 and 72 h after the final
dose. Values are mean ± SEM. Number of evaluable subjects for
LCI699 0.5, 1, 3 mg, eplerenone and placebo were n = 12, 12, 12, 10
and 9 respectively. *P < 0.05, †P < 0.01, ‡P < 0.001 vs placebo.
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terone production.
Characterization of LCI699 was performed using in vitro
assays and in vivo models in the rat and monkey. LCI699
showed distinct differences between species; it was at least
200-fold less potent in inhibiting rat recombinant adrenal
enzymes (and even less potent using rat adrenal tissue
homogenates) and ~20-fold less potent in inhibiting
monkey adrenal homogenate enzymes compared with
human recombinant enzymes. The in vivo Ang-II- and
ACTH-stimulation models used to characterize the
pharmacodynamic effects of LCI699 in rats and monkeys
predicted the human oral dose potency and the short
duration of action of LCI699 for inhibition of aldoster-
one synthase. Thus, LCI699 dose-dependently inhibited
ACTH-stimulated increases in aldosterone with an EC50
in the low nanomolar range in monkeys, consistent with
the low in vitro IC50 (0.7 nmol/L) obtained with recom-
binant human aldosterone synthase. Both the rat and
monkey in vitro data showed relative selectivity of LCI699
for aldosterone synthase over 11β-hydroxylase (3–5-fold)
similar to that observed with the human enzymes. How-
ever, both the rat and monkey in vivo models overesti-
mated the selectivity of LCI699 in humans. In the rat,
in vivo ED50 values showed 47-fold selectivity of LCI699
for aldosterone synthase over 11β-hydroxylase, while in
the monkey there was no attenuation of the ACTH-
stimulated cortisol response by LCI699 even at doses
above the ED50, which impaired cortisol synthesis inhuman subjects. Cai and co-workers evaluated the
effects of LCI699 (administered intravenously at doses
in the range 0.003–3 mg/kg) on ACTH-stimulated al-
dosterone and cortisol in rhesus monkeys on a low-salt
diet [25]. They showed no effect of LCI699 on ACTH-
stimulated cortisol at doses of 0.003–1 mg/kg, similar to
our findings in cynomologus monkeys with LCI699 (ad-
ministered orally at doses of 0.005–0.15 mg/kg). In rhesus
monkeys, only the highest, 3 mg/kg i.v. dose of LCI699 re-
duced ACTH-stimulated cortisol. Thus, the results of Cai
and co-workers [25] are consistent with our finding of a
relatively high in vivo selectivity of LCI699 for inhib-
ition of synthesis of aldosterone over cortisol in mon-
keys, which was not observed in humans. Overall, these
results demonstrate the utility and limitations of using
different species for in vitro and in vivo characterization
of ASIs and emphasize the importance of early human
investigations for selection of ASI drug candidates based
on potency and selectivity [26].
In the dTG rat model, inhibition of aldosterone synthase
with LCI699, which dose-dependently blocked increases
in aldosterone, prevented development of cardiac and
renal functional abnormalities (indicated by changes in LV
fractional shortening, IVRT/RR ratio, LV weight, BUN,
urinary albumin excretion), and reversed hormonal and
electrolyte abnormalities associated with elevated levels of
aldosterone. It is noteworthy that the organ protective
effects of aldosterone synthase inhibition with LCI699
occurred in the absence of any major reduction in
blood pressure. The correlations between plasma aldoster-
one concentration and observed cardiac and renal struc-
tural and functional abnormalities in the present study
(Additional file 4) provide additional evidence in support
of direct deleterious effects of aldosterone on the heart
and kidneys. In addition, dTG rats were polydipsic and
polyuric (4-fold higher urine volume flow compared with
S-D rats). While Ang-II-induced hypertension with result-
ing pressure natriuresis has been suggested as the cause
for the increase in urine volume [27], our observation that
LCI699 normalized urine volume in dTG rats with little
effect on blood pressure indicates that other mechanisms
may play a more important role such as impaired renal
concentrating ability associated with hyperaldosteronism
and hypokalemia [27]. The finding that aldosterone
synthase inhibition exerts organ protective effects inde-
pendent of blood pressure lowering also suggests that
blood pressure should not be used as the sole surrogate
marker of cardiorenal risk reduction in early clinical
testing of ASIs.
LCI699 prolonged survival in both young dTG rats
and older animals with established hypertension and
cardiorenal disease. The MRA eplerenone at a dose of
30 mg/kg body weight also improved survival in a young
dTG rat model, but increased plasma and urinary
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of cardiorenal damage that were normalized by LCI699.
Our results confirm and extend those of Fiebeler et al.,
who showed that the aldosterone synthase (CYP11B2)
inhibitor FAD286 or adrenalectomy attenuated cardior-
enal damage and reduced mortality in young dTG rats
[28]. Collectively, these data suggest that aldosterone, in
addition to Ang II and hypertension, is an important
mediator of cardiac and renal damage in the dTG rat
model. Synergistic genomic and non-genomic interac-
tions between aldosterone and Ang II have been de-
scribed in both in vitro and in vivo studies, and have
been implicated in vascular inflammation, fibrosis and re-
modeling [29,30]. Although corticosterone, the physiologic
glucocorticoid in rodents, and cortisol in humans have
the same affinity for the mineralocorticoid receptor as
aldosterone and are present in higher concentrations
than aldosterone [31], plasma corticosterone levels in
dTG rats were not higher than those observed in age-
matched S-D rats and so it is unlikely that corti-
costerone contributed significantly to the cardiorenal
disease observed in the dTG rat model. It is notable that
enalapril pre-treatment extended median survival by
approximately 4 months in the dTG rat. This may be
due to the cardiorenal protective effects of reducing
Ang II levels by inhibiting ACE that may influence
survival beyond what can be achieved by inhibition of
aldosterone synthesis. Regardless of possible synergy
between Ang II and aldosterone, our results indicate
that inhibiting aldosterone synthase alone is sufficient
to prevent development and slow progression of cardiac
and renal disease in the dTG rat model.
LCI699 was synthesized as the first orally active aldos-
terone synthase inhibitor for human use based on the
chemical structure of FAD286A, the dextroenantiomer
of the aromatase inhibitor fadrozole. Studies in recom-
binant hamster fibroblasts expressing human CYP11B1
and CYP11B2 showed that LCI699 was a more potent in-
hibitor of aldosterone synthesis than FAD286A (IC50
0.2 vs 0.8 nmol/L) and more selective for inhibition of
aldosterone vs cortisol synthesis (selectivity factor 15-fold
vs 7.9-fold) [32]. However, selectivity of LCI699 for aldos-
terone synthase over 11β-hydroxylase was comparable
to that for FAD286 based on recombinant human
CYP11B1 and CYP11B2 enzymatic assays [20]. LCI699
and FAD286A also exhibited broadly similar selectivity
for inhibition of aldosterone synthase over 11β-hydroxylase
in the in vivo rat ACTH stimulation model (selectivity
factor by exposure 47-fold for LCI699 in the present
study, vs 48-fold for FAD286A in a previous study) [21].
Preclinical studies in dogs showed that LCI699 exhib-
ited greater oral bioavailability than FAD286A (96% vs
33% for a 1 mg/kg oral dose), a longer half-life
(0.6–3.6 h vs 0.9–1.2 h), and more potent inhibition ofAng II-stimulated aldosterone release (EC50 41 nmol/L vs
136 nmol/L) (D. Rigel, personal communication). FAD286A
was tested in a similar dTG rat model to that used in the
present study [28]. The effects of FAD286A (4 mg/kg in
the diet from Weeks 4–7) on albuminuria and cardiac
hypertrophy appeared less pronounced than those that
we observed with LCI699; however, subsequent studies
using higher doses of FAD286A found comparable pharma-
cologic benefits of LCI699 and FAD286A (D. Rigel, per-
sonal communication).
It is important to consider the potential differences in
clinical benefit between inhibiting the synthesis of aldos-
terone with an ASI and inhibiting the mineralocorticoid
receptor with an MRA. These have been reviewed in
detail, with specific reference to LCI699, by Azizi and
colleagues [33]. One issue of particular clinical relevance
is hyperkalemia, which is a well-known adverse effect of
MRAs and other inhibitors of RAS activity. It is, how-
ever, uncertain if the different mechanism of action of
ASIs compared with MRAs will alter the risk of hyper-
kalemia. Some insights may be gained by comparing the
phenotypes of mineralocorticoid receptor- and aldoster-
one synthase-deficient mice generated by gene targeting.
Mineralocorticoid receptor-deficient mice show a partial
defect of the amiloride-sensitive Na+ channel (ENaC) in
the colon and kidney [34,35]. The phenotype is cha-
racterized by strongly enhanced fractional excretion of
sodium resulting in hyponatremia and severe hyperkale-
mia with reduced fractional excretion of potassium com-
pared with wild type mice, reflecting a transport defect
in the principal cells of the collecting duct. In contrast,
mice with genetic deficiency of aldosterone synthase
demonstrate modest hyperkalemia with normal urinary
potassium excretion [36]. Interestingly, an increase in
potassium excretion on Day 7 was observed in our
study of healthy subjects following administration of
LCI699, but not eplerenone. One possible explanation
for this difference is that 11-DOC (increased by LCI699
but not eplerenone) which been shown to stimulate
potassium excretion in the renal collecting tubules, may
have a relative potassium-sparing effect without pro-
moting sodium retention [37,38]. The clinical relevance
of this remains uncertain, however, as a study conducted
in patients with mild-to-moderate hypertension showed a
significant dose-response relationship for LCI699 (total
daily dose range 0.25 mg to 1 mg) and serum potassium
levels; moreover, changes in serum potassium concentra-
tion with LCI699 were similar in magnitude to those ob-
served with the MRA eplerenone (50 mg twice daily) [39].
The clinical benefits of MRAs have been demonstrated
previously [3-5]. However, the efficacy of MRAs may be
limited by the fact that the renal loss of sodium and reten-
tion of potassium induced by MRAs stimulate a dose-
dependent increase in renin, Ang II and aldosterone [7].
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ment both by competition of increased aldosterone at the
level of the mineralocorticoid receptor and by stimulating
non-genomic (mineralocorticoid receptor-independent)
effects of aldosterone [40]. On the other hand, cardiom-
yocyte mineralocorticoid receptors can be occupied by
physiologic glucocorticoids, and under conditions of tissue
damage cortisol can become a mineralocorticoid receptor
agonist [41], mimicking the experimental effects of
aldosterone through a mechanism that would not be
affected by an ASI. Our results that cardiomyocyte cell
size was normalized by LCI699 in the dTG rat suggest
that such a mechanism plays little, if any, role in this
experimental model.
The majority of untreated dTG rats in our studies ex-
perienced unexpected and sudden death, whereas the
majority of LCI699-treated animals eventually became
moribund, necessitating euthanasia. Although the mode
of death is uncertain, it is possible that inhibiting aldos-
terone synthase may reduce mortality in part by prevent-
ing sustained ventricular arrhythmias and subsequent
hemodynamic deterioration [42]. The clinical relevance
of such findings is suggested by the Randomized ALdac-
tone Evaluation Study (RALES), which demonstrated
that in patients with congestive heart failure, the
addition of spironolactone to standard medical therapy
significantly reduced both cardiac mortality and sudden
cardiac death [3].
This study provides the first comprehensive characte-
rization of the hormonal effects of inhibiting aldosterone
synthase in humans. In the clinical study, moderate sodium
restriction was used to activate the renin-angiotensin path-
way and stimulate baseline aldosterone levels, and thereby
facilitate detection of dose-dependent decreases in aldoster-
one and counter-regulatory increases in renin. Sodium and
potassium intake were strictly controlled while subjects
were housed in the clinic and verified by measuring urinary
sodium and potassium excretion. The potassium content of
the diet was increased by 20 mEq/day after 7 days to evalu-
ate the persistence of LCI699 effects in response to further
stimulation of aldosterone release. Single doses of LCI699
caused dose-dependent reductions in plasma and urinary
aldosterone levels; the maximal inhibition of plasma aldos-
terone reached a plateau of approximately 80% at the
10 mg single dose, with no further reduction at higher
doses up to 200 mg. These results were consistent with
those from the Ang-II- and ACTH-stimulation models
in rats and monkeys, in which the upper dose of LCI699
also did not completely inhibit aldosterone production
(maximal inhibition of 80–90%). Incomplete pharmaco-
logic inhibition of aldosterone synthase by LCI699 at
the doses used is the most likely explanation for this ob-
servation, because in monkeys a 3000 μg/kg dose of
LCI699 decreased plasma aldosterone concentrations tobelow the detection limit for 24 h (data not shown).
Indeed, the steroid profile of patients with genetic
aldosterone synthase deficiency is characterized by low
to undetectable plasma aldosterone levels and elevated
levels of mineralocorticoid precursors (corticosterone
or 11-DOC) [16].
LCI699 treatment induced a natriuresis on Day 1 that
was similar with all doses and equal to that achieved by
eplerenone 100 mg (the approved maximum once-daily
dose for use in patients with essential hypertension).
The rise in PRA observed after repeated administration of
LCI699 reflects the magnitude of RAS counter-regulation
following aldosterone synthase inhibition and consequent
aldosterone suppression and sodium depletion. LCI699
0.5 mg daily resulted in similar increases in PRA to eplere-
none 100 mg, while LCI699 3 mg stimulated markedly
larger increases in PRA. The larger dose-dependent
counter-regulatory activation of the RAS by LCI699
relative to eplerenone presumably reflects greater sup-
pression of the aldosterone pathway by LCI699 at the
higher doses. The consequent increase in levels of Ang
II may limit effects of aldosterone synthase inhibition,
but this was not tested in the present study.
Repeated once-daily dosing with LCI699 was associated
with a resetting of plasma aldosterone levels during the
second half of the dosing interval (12–24 h post-dose)
followed by a more gradual, chronic increase in baseline
aldosterone levels. This pattern probably reflects a com-
bination of the short half-life of LCI699 (approximately
4 h in humans), counter-regulatory stimulation of the
RAS, a gradual increase in adrenal aldosterone synthase
enzyme, and slow clearance of precursors such as
11-DOC. In the first 12 h after dosing, LCI699 effect-
ively inhibited the activity of aldosterone synthase and
plasma aldosterone was decreased. However, during
the next 12 h, when LCI699 plasma concentrations had
decreased, aldosterone synthase was presumably no
longer inhibited. Moreover, the adrenal gland was
exposed to elevated levels of renin and Ang II, which
stimulate aldosterone release [43]. Thus, with once-daily
administration of LCI699 in the morning, the pharmaco-
logic effect of the drug to inhibit aldosterone synthase will
essentially have dissipated during the nocturnal rise in
ACTH, cortisol and aldosterone. This was the pharmaco-
kinetic and dynamic basis for twice-daily dosing of LCI699
for subsequent studies in patients.
The selectivity of LCI699 for aldosterone synthase over
11β-hydroxylase was evaluated by an ACTH stimulation
test in experimental models and in humans. The ACTH
test provided safety monitoring for clinically relevant in-
hibition of glucocorticoid synthesis, which occurred with
repeated administration of LCI699 at the 10 mg dose
[44]. Measurements of plasma levels of precursors of
aldosterone synthesis (11-DOC) and cortisol synthesis
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relative selectivity of aldosterone synthase inhibition.
Both precursors are synthesized in the adrenal gland
and their production is dependent on normal ACTH
levels [45,46]. LCI699 0.5 mg was shown to be selective for
inhibition of aldosterone synthase over 11β-hydroxylase
throughout the dosing period, as evidenced by reductions
in plasma and urinary aldosterone and increases in the
aldosterone precursor 11-DOC without effect on basal or
ACTH-stimulated cortisol or on the cortisol precursor
11-deoxycortisol. LCI699 1 mg was selective for aldos-
terone synthase after a single dose on Day 1 and on Day
6 of multiple dose administration, but showed a time-
dependent loss of selectivity with continued dosing.
Although there was no effect on basal cortisol or 11-
deoxycortisol, LCI699 1 mg did result in attenuation of
the ACTH-stimulated cortisol response on Day 13. This
was confirmed in approximately 20% of hypertensive
patients treated with LCI699 1 mg once daily [47]. This
lag in pharmacodynamic effect in the absence of a
change in plasma pharmacokinetics, may reflect a longer
half-life of LCI699 within the adrenals. The 3 mg dose of
LCI699 inhibited 11β-hydroxylase on Day 6 (as demon-
strated by both an attenuated cortisol response to ACTH
and increase in 11-deoxycortisol) and also resulted in a
small increase in plasma potassium which, in conjunction
with the clinical observations, suggested development of
mild hypoaldosteronism.
Several limitations of the human study should be
acknowledged. First, although dietary sodium and potas-
sium intake were controlled, there was no assessment of
total metabolic sodium and potassium balance during
repeated dose administration of LCI699. Second, urinary
collections were not fractionated. This likely gave rise to
an artifactual apparent attenuation in the effect of LCI699
to inhibit aldosterone synthase when 24-h urinary aldos-
terone was compared across Days 1, 7 and 14 of adminis-
tration because of the short half-life of LCI699 and
consequent rebound increase in aldosterone 12–24 h after
dosing.
There are two potential therapeutic uses of LCI699, as
noted by Azizi and colleagues in their review of the
therapeutic potential of aldosterone synthase inhibition
[33]. First, LCI699 at low doses (below 1 mg) can be used
as a selective inhibitor of aldosterone production to treat
subsets of patients with hypertension and cardiorenal dis-
ease associated with elevated aldosterone levels. In a small,
short-term study in 14 patients with primary aldosteron-
ism, LCI699 (0.5 mg and 1 mg) administered twice daily
effectively reduced plasma and urinary aldosterone levels
and corrected hypokalemia after 4 weeks of treatment. In
these low-renin hypertensive patients, reductions in blood
pressure were very modest (mean 4 mmHg decrease in
ambulatory systolic blood pressure) [48]. In another studyof 524 patients with essential hypertension, LCI699 ad-
ministered at doses between 0.25 and 1 mg resulted in
placebo-corrected reductions in ambulatory systolic and
diastolic blood pressures of 6–9 mmHg and 3–6 mmHg,
respectively after 8 weeks of treatment [39]; ACTH-
stimulated cortisol release was suppressed in approxi-
mately 20% of subjects receiving LCI699 at a total daily
dose of 1 mg in that study. Second, the potency of LCI699
in inhibiting 11β-hydroxylase at daily doses above 3 mg
led to further development of LCI699 as a drug candidate
for indications in which metyrapone is currently used,
both for diagnosis and treatment. Indeed, LCI699 has low
pharmacokinetic variability, and may avoid the limitations
of metyrapone and other steroidogenesis inhibitors such
as ketoconazole and mitotane [49]. In a study in
12 patients with Cushing’s disease, LCI699 2–50 mg
twice daily was well tolerated and highly effective in
reducing urinary free cortisol (below upper limit of
normal in 11 patients) and in lowering blood pressure
after 70 days of treatment [19].
Conclusions
The results of this study of aldosterone synthase inhib-
ition in several cell systems and animal models and their
translation to humans provides a rationale and method-
ology for further investigations to assess the therapeutic
potential of new ASIs in chronic diseases characterized
by aldosterone excess. Our observations in the dTG rat
model suggest that ASIs may be clinically useful in pre-
venting or minimizing the deleterious effects of aldoster-
one on the heart and kidney and in reducing mortality.
Additional files
Additional file 1: Supplementary methods.
Additional file 2: Pharmacokinetic profile of LCI699 in rat and
monkey in vivo models. Plasma concentration–time profiles for
LCI699 after administration in (A) the angiotensin-II-stimulated rat
model, (B) the adrenocorticotropic hormone (ACTH)-infusion rat model
and (C) the ACTH-stimulated monkey model. Plasma concentrations of
LCI699 after administration of the 5 μg/kg dose in monkeys were
below the limit of detection. Values are means. Number of evaluable
animals was n = 3 per dose group.
Additional file 3: Effect of LCI699 on Ang-II- and ACTH-stimulated
levels of aldosterone and corticosterone in rats. (A) Mean plasma
aldosterone concentrations in the Ang-II-infusion model, and (B) mean plasma
aldosterone concentrations and (C) plasma corticosterone concentrations in
the ACTH-infusion model after oral administration of LCI699. Ang II infusion
(initial loading dose of 300 ng/kg then 100 ng/kg/min) was started 1 h before
dosing with LCI699 (time 0 h) and continued until 8 h after dosing.
ACTH infusion (initial loading dose of 100 ng/kg then 30 ng/kg/min)
was started 1 h before dosing with LCI699 (vertical dotted line; time 0 h)
and continued until 8 h after dosing. Values are means. Number of evaluable
animals was n = 3 per dose group.
Additional file 4: Correlation of plasma aldosterone concentrations
with cardiac weight, size and function and with renal function.
Correlation of plasma aldosterone concentrations with (A) left ventricular
(LV) fractional shortening (FS), (B) LV isovolumic relaxation time (IVRT) as a
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TL), (D) LV myocardial cell size, (E) blood urea nitrogen (BUN) and (F) 24 h
urinary albumin excretion (UAE). Each point represents an individual animal,
and data are pooled across all dTG rats (controls and LCI699-treated).
Measurements were taken at 7 weeks of age. R2 and corresponding
P values are indicated in each panel.
Additional file 5: Pharmacokinetic profile of LCI699 following a
single oral dose in humans. (A) Plasma concentration–time profile for
LCI699 (mg dose of phosphate salt) on Day 1 following single-dose
administration in healthy human volunteers. Values are mean ± SD.
Number of evaluable subjects is presented in parentheses. Data presented
come from the single-dose phase and first dose of the multiple-ascending
dose phase; samples were taken only up to 48 h during this phase. (B)
Dose-proportionality plot for LCI699. Values (on a logarithmic scale) are
mean ± SD area under the plasma concentration–time curve from 0–24 h
(AUC0–24h) on Day 1.
Additional file 6: Effect of LCI699 on plasma and urinary cortisol
concentrations (human study, multiple-dose phase). (A) mean plasma
cortisol concentrations and (B) percentage change in 24 hour urinary
aldosterone from time-matched baseline on Day 1 following administration
of LCI699 (0.5, 1 or 3 mg), eplerenone (100 mg) or placebo in healthy
human volunteers. Values are mean ± SEM. Number of evaluable subjects
for LCI699 0.5, 1, 3, 10 mg, eplerenone and placebo were (plasma) n = 12,
12, 12, 5, 10 and 11 respectively, and (urine) n = 12, 12, 12, 5, 10 and 11
respectively.
Abbreviations
AAR: Adrenodoxin-adrenodoxin reductase; ACE: Angiotensin-converting
enzyme; ACTH: Adrenocorticotropic hormone; ANCOVA: Analysis of
covariance; Ang II: Angiotensin II; ANOVA: Analysis of variance;
ASIs: Aldosterone synthase inhibitors; AUC: Area under curve; bpm: Beats per
minute; BUN: Blood urea nitrogen; CCr: Creatinine clearance; Cmax: Maximum
plasma concentrations; CI: Confidence interval; CYP: Cytochrome P450;
DBP: Diastolic blood pressure; 11-DOC: 11-deoxycorticosterone; dTG:
Double-transgenic; EC50: Half maximal effective concentration; ED50:
Half-maximal effective dose; EDTA: Ethylenediaminetetraacetic acid;
EIA: Enzyme Immunoassay; ENaC: Epithelial sodium channel; fps: Frames
per second; FS: Fractional shortening; HR: Heart rate; IC50: Half maximal
inhibitory concentration; i.v.: Intravenous; IVRT: Isovolumic relaxation time;
Ki: Inhibitor constant; LC-MS/MS: Liquid chromatography-tandem mass
spectrometry; LV: Left ventricular; LVW/TL: LV weight normalized to tibial
length; MAP: Mean arterial pressure; MRAs: Mineralocorticoid receptor
antagonists; PAC: Plasma aldosterone concentration; PRA: Plasma renin
activity; RALES: Randomized ALdactone Evaluation Study; RAS:
Renin-angiotensin system; SBP: Systolic blood pressure; SD: Standard
deviation; S-D: Sprague-Dawley; SEM: Standard error of the mean; t½:
Half-life; TDI: Time delay and integration; tmax: Time to maximum plasma
concentration; UAE: Urinary albumin excretion; UAldoE: Urinary
aldosterone excretion; VAP: Vascular access port.
Competing interests
JM has received fees as a consultant to Novartis, Actelion, Roche and NicOx,
and has received no stock or stock options. DFR, CW, FF, MB, JL, WC, DL, GL,
SR, YZ and WPD are employees of Novartis and are therefore eligible for
Novartis stock and stock options. AYJ was formerly an employee of Novartis.
Authors’ contributions
All authors made substantial contributions to the conception or design of
the work and/or the acquisition, analysis, or interpretation of data for the
work. JM and WPD were responsible for the design of the overall study
program, preclinical and clinical data analysis and interpretation. DFR was
responsible for the design and oversight of preclinical rat and monkey
in vivo studies, and data analysis and interpretation. AYJ was responsible for
the design and oversight of in vitro assays and preclinical rat and monkey
ex vivo sample analyses, and data analysis and interpretation. FF, MB, JL and
WC were responsible for the conduct and data analysis of preclinical rat and
monkey in vivo studies. CH and JL were responsible for analysis of preclinical
rat and monkey ex vivo samples and data. DL was responsible for conduct of
in vitro assays and data analysis. GL was responsible for the analysis of
preclinical rat and monkey pharmacokinetic samples and data. SR wasresponsible for the analysis of clinical pharmacokinetic data and its
interpretation. YZ was responsible for the analysis of clinical study data. CW
was responsible for the design and oversight of the clinical study conduct
and summary and interpretation of its data. All authors were involved with
drafting the manuscript or revising it critically for important intellectual
content, and approved the final version of the manuscript. In addition, all
authors agree to be accountable for all aspects of the work in ensuring that
questions related to the accuracy or integrity of any part of the work are
appropriately investigated and resolved.
Acknowledgements
The authors thank Qing Nie and Drs Jennifer Allport-Anderson, Martina
Schinke-Braun and Gordon Turner for the ventricular cell size determinations,
Della DeRaismes and Liane Yanas for the clinical chemistry analyses, and Dr
Martin Beibel for the survival statistics. The monkey studies would not have
been possible without the dedicated assistance and support of John Arzadon,
Nicole Ecklof, Kellyann Kovach, Josephine Perez and Dr Mikele Simkins. The
authors acknowledge Georg Golor MD PhD, Parexel International GmbH, Berlin,
Germany; Jan Jaap van Lier MD, PRA, Zuidlaren, Netherlands and Thijs van
Lier, Xendo, Gronigen, Netherlands as the centre leads for the clinical study.
The authors acknowledge the editorial assistance of Dr Richard White
(Oxford PharmaGenesis Ltd) in collating the comments of individual
reviewers and editing the final version of the manuscript; funding for this
work was provided by Novartis.
Author details
1Université Paris Descartes, Faculté de Médecine and INSERM/AP-HP Clinical
Investigation Center, Georges Pompidou Hospital, Paris, France. 2Novartis
Pharmaceuticals Corporation, East Hanover, NJ, USA. 3Novartis Institutes for
BioMedical Research, Cambridge, MA, USA. 4Current address: Golda Och
Academy, 1418 Pleasant Valley Way, West Orange, NJ 07052, USA.
Received: 19 September 2014 Accepted: 22 November 2014
References
1. Williams GH: Essential hypertension as an endocrine disease. Endocrinol
Metab Clin North Am 1994, 23:429–444.
2. Joffe HV, Adler GK: Effect of aldosterone and mineralocorticoid receptor
blockade on vascular inflammation. Heart Fail Rev 2005, 10:31–37.
3. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J,
Wittes J: The effect of spironolactone on morbidity and mortality in
patients with severe heart failure. Randomized Aldactone Evaluation
Study Investigators. N Engl J Med 1999, 341:709–717.
4. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R,
Hurley S, Kleiman J, Gatlin M: Eplerenone, a selective aldosterone blocker,
in patients with left ventricular dysfunction after myocardial infarction.
N Engl J Med 2003, 348:1309–1321.
5. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H,
Vincent J, Pocock SJ, Pitt B: Eplerenone in patients with systolic heart
failure and mild symptoms. N Engl J Med 2011, 364:11–21.
6. Laragh JH: Vasoconstriction-volume analysis for understanding and
treating hypertension: the use of renin and aldosterone profiles. Am J
Med 1973, 55:261–274.
7. Ramsay LE, Hettiarachchi J, Fraser R, Morton JJ: Amiloride, spironolactone,
and potassium chloride in thiazide-treated hypertensive patients.
Clin Pharmacol Ther 1980, 27:533–543.
8. Chun TY, Pratt JH: Nongenomic renal effects of aldosterone: dependency
on NO and genomic actions. Hypertension 2006, 47:636–637.
9. Mihailidou AS, Funder JW: Nongenomic effects of mineralocorticoid
receptor activation in the cardiovascular system. Steroids 2005, 70:347–351.
10. Wehling M: Specific, nongenomic actions of steroid hormones. Annu Rev
Physiol 1997, 59:365–393.
11. Struthers AD: Aldosterone escape during ACE inhibitor therapy in chronic
heart failure. Eur Heart J 1995, 16 Suppl N:103–106.
12. Staessen J, Lijnen P, Fagard R, Verschueren LJ, Amery A: Rise in plasma
concentration of aldosterone during long-term angiotensin II suppression.
J Endocrinol 1981, 91:457–465.
13. Taves MD, Gomez-Sanchez CE, Soma KK: Extra-adrenal glucocorticoids and
mineralocorticoids: evidence for local synthesis, regulation, and function.
Am J Physiol Endocrinol Metab 2011, 301:E11–E24.
Ménard et al. Journal of Translational Medicine  (2014) 12:340 Page 22 of 2214. Silvestre JS, Heymes C, Oubenaissa A, Robert V, Aupetit-Faisant B, Carayon A,
Swynghedauw B, Delcayre C: Activation of cardiac aldosterone production
in rat myocardial infarction: effect of angiotensin II receptor blockade
and role in cardiac fibrosis. Circulation 1999, 99:2694–2701.
15. White PC: Aldosterone synthase deficiency and related disorders. Mol Cell
Endocrinol 2004, 217:81–87.
16. Veldhuis JD, Melby JC: Isolated aldosterone deficiency in man: acquired
and inborn errors in the biosynthesis or action of aldosterone. Endocr Rev
1981, 2:495–517.
17. Meredith EL, Ksander G, Monovich LG, Papillon JP, Liu Q, Miranda K, Morris
P, Rao C, Burgis R, Capparelli M, Hu QY, Singh A, Rigel DF, Jeng AY, Beil M,
Fu F, Hu CW, LaSala D: Discovery and in vivo evaluation of potent dual
CYP11B2 (Aldosterone Synthase) and CYP11B1 inhibitors. ACS Med Chem
Lett 2013, 4:1203–1207.
18. Hakki T, Bernhardt R: CYP17- and CYP11B-dependent steroid hydroxylases
as drug development targets. Pharmacol Ther 2006, 111:27–52.
19. Bertagna X, Pivonello R, Fleseriu M, Zhang Y, Robinson P, Taylor A, Watson
CE, Maldonado M, Hamrahian AH, Boscaro M, Biller BM: LCI699, a potent
11beta-hydroxylase inhibitor, normalizes urinary cortisol in patients with
Cushing’s disease: results from a multicenter, proof-of-concept study.
J Clin Endocrinol Metab 2014, 99:1375–1383.
20. LaSala D, Shibanaka Y, Jeng AY: Coexpression of CYP11B2 or CYP11B1 with
adrenodoxin and adrenodoxin reductase for assessing the potency and
selectivity of aldosterone synthase inhibitors. Anal Biochem 2009, 394:56–61.
21. Rigel DF, Fu F, Beil M, Hu CW, Liang G, Jeng AY: Pharmacodynamic and
pharmacokinetic characterization of the aldosterone synthase inhibitor
FAD286 in two rodent models of hyperaldosteronism: comparison with
the 11beta-hydroxylase inhibitor metyrapone. J Pharmacol Exp Ther 2010,
334:232–243.
22. Bohlender J, Fukamizu A, Lippoldt A, Nomura T, Dietz R, Menard J,
Murakami K, Luft FC, Ganten D: High human renin hypertension in
transgenic rats. Hypertension 1997, 29:428–434.
23. St-Jacques R, Toulmond S, Auger A, Binkert C, Cromlish W, Fischli W, Harris J,
Hess P, Jie L, Liu S, Riendeau D, Steiner B, Percival MD: Characterization of a
stable, hypertensive rat model suitable for the consecutive evaluation of
human renin inhibitors. J Renin Angiotensin Aldosterone Syst 2011, 12:133–145.
24. Gough K, Hutchison M, Keene O, Byrom W, Ellis S, Lacey L, McKellar J:
Assessment of dose proportionality: report from the Statisticians in the
Pharmaceutical Industry/Pharmacokinetics UK Joint Working Party.
Drug Inf J 1995, 29:1039–1048.
25. Cai TQ, Stribling S, Tong X, Xu L, Wisniewski T, Fontenot JA, Struthers M,
Akinsanya KO: Rhesus monkey model for concurrent analyses of in vivo
selectivity, pharmacokinetics and pharmacodynamics of aldosterone
synthase inhibitors. J Pharmacol Toxicol Methods 2014, doi:10.1016/j.
vascn.2014.09.011.
26. Hu Q, Yin L, Hartmann RW: Aldosterone synthase inhibitors as promising
treatments for mineralocorticoid dependent cardiovascular and renal
diseases. J Med Chem 2014, e-pub ahead of print, doi:10.1021/jm401430e.
27. Berl T, Linas SL, Aisenbrey GA, Anderson RJ: On the mechanism of polyuria
in potassium depletion. The role of polydipsia. J Clin Invest 1977,
60:620–625.
28. Fiebeler A, Nussberger J, Shagdarsuren E, Rong S, Hilfenhaus G, Al-Saadi N,
Dechend R, Wellner M, Meiners S, Maser-Gluth C, Jeng AY, Webb RL, Luft
FC, Muller DN: Aldosterone synthase inhibitor ameliorates angiotensin
II-induced organ damage. Circulation 2005, 111:3087–3094.
29. Min LJ, Mogi M, Li JM, Iwanami J, Iwai M, Horiuchi M: Aldosterone and
angiotensin II synergistically induce mitogenic response in vascular
smooth muscle cells. Circ Res 2005, 97:434–442.
30. Montezano AC, Callera GE, Yogi A, He Y, Tostes RC, He G, Schiffrin EL, Touyz
RM: Aldosterone and angiotensin II synergistically stimulate migration in
vascular smooth muscle cells through c-Src-regulated redox-sensitive
RhoA pathways. Arterioscler Thromb Vasc Biol 2008, 28:1511–1518.
31. Gomez-Sanchez EP: The mammalian mineralocorticoid receptor: tying
down a promiscuous receptor. Exp Physiol 2010, 95:13–18.
32. Yin L, Hu Q, Emmerich J, Lo MM, Metzger E, Ali A, Hartmann RW: Novel
pyridyl- or isoquinolinyl-substituted indolines and indoles as potent and
selective aldosterone synthase inhibitors. J Med Chem 2014, 57:5179–5189.
33. Azizi M, Amar L, Menard J: Aldosterone synthase inhibition in humans.
Nephrol Dial Transplant 2013, 28:36–43.
34. Berger S, Bleich M, Schmid W, Cole TJ, Peters J, Watanabe H, Kriz W, Warth
R, Greger R, Schutz G: Mineralocorticoid receptor knockout mice:pathophysiology of Na+ metabolism. Proc Natl Acad Sci U S A 1998,
95:9424–9429.
35. Bleich M, Warth R, Schmidt-Hieber M, Schulz-Baldes A, Hasselblatt P,
Fisch D, Berger S, Kunzelmann K, Kriz W, Schutz G, Greger R: Rescue of
the mineralocorticoid receptor knock-out mouse. Pflugers Arch 1999,
438:245–254.
36. Makhanova N, Sequeira-Lopez ML, Gomez RA, Kim HS, Smithies O:
Disturbed homeostasis in sodium-restricted mice heterozygous and
homozygous for aldosterone synthase gene disruption. Hypertension
2006, 48:1151–1159.
37. O’Neil RG, Helman SI: Transport characteristics of renal collecting tubules:
influences of DOCA and diet. Am J Physiol 1977, 233:F544–F558.
38. Peterson LN, Wright FS: Effect of sodium intake on renal potassium
excretion. Am J Physiol 1977, 233:F225–F234.
39. Calhoun DA, White WB, Krum H, Guo W, Bermann G, Trapani A, Lefkowitz MP,
Menard J: Effects of a novel aldosterone synthase inhibitor for treatment of
primary hypertension: results of a randomized, double-blind, placebo- and
active-controlled phase 2 trial. Circulation 2011, 124:1945–1955.
40. Brown R, Quirk J, Kirkpatrick P: Eplerenone. Nat Rev Drug Discov 2003,
2:177–178.
41. Mihailidou AS, Le Loan TY, Mardini M, Funder JW: Glucocorticoids activate
cardiac mineralocorticoid receptors during experimental myocardial
infarction. Hypertension 2009, 54:1306–1312.
42. Fischer R, Dechend R, Gapelyuk A, Shagdarsuren E, Gruner K, Gruner A,
Gratze P, Qadri F, Wellner M, Fiebeler A, Dietz R, Luft FC, Muller DN,
Schirdewan A: Angiotensin II-induced sudden arrhythmic death and
electrical remodeling. Am J Physiol Heart Circ Physiol 2007,
293:H1242–H1253.
43. Young DB: Quantitative analysis of aldosterone’s role in potassium
regulation. Am J Physiol 1988, 255:F811–F822.
44. Kazlauskaite R, Evans AT, Villabona CV, Abdu TA, Ambrosi B, Atkinson AB,
Choi CH, Clayton RN, Courtney CH, Gonc EN, Maghnie M, Rose SR, Soule SG,
Tordjman K: Corticotropin tests for hypothalamic-pituitary- adrenal
insufficiency: a metaanalysis. J Clin Endocrinol Metab 2008, 93:4245–4253.
45. Coppage WS Jr, Island D, Smith M, Liddle GW: Inhibition of aldosterone
secretion and modification of electrolyte excretion in man by a chemical
inhibitor of 11 beta-hydroxylation. J Clin Invest 1959, 38:2101–2110.
46. Liddle GW, Island D, Lance EM, Harris AP: Alterations of adrenal steroid
patterns in man resulting from treatment with a chemical inhibitor of 11
beta-hydroxylation. J Clin Endocrinol Metab 1958, 18:906–912.
47. White WB, Calhoun DA, Krum H, Guo W, Trapani AJ, Lefkowitz M, Menard J:
Blockade of aldosterone production as a novel approach to the
management of high blood pressure: efficacy and tolerability of the
aldosterone synthase inhibitor LCI699 in patients with stage 1-2
hypertension. J Am Coll Cardiol 2010, 55:A61.E582.
48. Amar L, Azizi M, Menard J, Peyrard S, Watson C, Plouin PF: Aldosterone
synthase inhibition with LCI699: a proof-of-concept study in patients
with primary aldosteronism. Hypertension 2010, 56:831–838.
49. Biller BM, Grossman AB, Stewart PM, Melmed S, Bertagna X, Bertherat J,
Buchfelder M, Colao A, Hermus AR, Hofland LJ, Klibanski A, Lacroix A, Lindsay
JR, Newell-Price J, Nieman LK, Petersenn S, Sonino N, Stalla GK, Swearingen B,
Vance ML, Wass JA, Boscaro M: Treatment of adrenocorticotropin-dependent
Cushing’s syndrome: a consensus statement. J Clin Endocrinol Metab 2008,
93:2454–2462.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
